BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics
BTAI Price/Volume Stats
| Current price | $1.84 | 52-week high | $25.12 |
| Prev. close | $1.53 | 52-week low | $1.17 |
| Day low | $1.55 | Volume | 275,631 |
| Day high | $1.84 | Avg. volume | 2,754,919 |
| 50-day MA | $1.65 | Dividend yield | N/A |
| 200-day MA | $5.59 | Market Cap | 11.14M |
BTAI Stock Price Chart Interactive Chart >
BioXcel Therapeutics, Inc. (BTAI) Company Bio
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
BTAI Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BTAI Price Returns
| 1-mo | 20.26% |
| 3-mo | -45.40% |
| 6-mo | -71.80% |
| 1-year | -92.23% |
| 3-year | -99.00% |
| 5-year | -99.76% |
| YTD | -69.24% |
| 2024 | -87.33% |
| 2023 | -86.27% |
| 2022 | 5.66% |
| 2021 | -56.00% |
| 2020 | 216.22% |